OINDPnews


Copley Scientific banner

Business

Lee’s Pharmaceutical to acquire controlling interest in Windtree Therapeutics

Hong Kong-based Lee's Pharmaceutical will advance Windtree Therapeutics up to $3.9 million through the end of October 2017 during negotiations for Lee's to acquire a controlling interest in Windtree. The first installment of the loan has already been received by Windtree, the company said. In June 2017, Windtree announced that Lee's had acquired the rights to … [Read more...] about Lee’s Pharmaceutical to acquire controlling interest in Windtree Therapeutics

Aradigm gets SBIR grant for development of Linhaliq and Lipoquin for NTM

Aradigm Corporation has received a 2-year Small Business Initiative Research (SBIR) grant of about $972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) for development of Linhaliq and Lipoquin to treat pulmonary non-tuberculous mycobacteria (NTM) infections, the company said. The grant will support … [Read more...] about Aradigm gets SBIR grant for development of Linhaliq and Lipoquin for NTM

Verona Pharma developing MDI and DPI formulations of RPL554

According to Verona Pharma's mid-year update, the company is developing MDI and DPI formulations of its RPL554, an inhaled PDE3/PDE4 inhibitor. Nebulized RPL554 is currently in Phase 2 development, and Verona reported positive results from a Phase 2a trial of RPL554 for the treatment of acute exacerbations in COPD patients in March 2016. The company said that it … [Read more...] about Verona Pharma developing MDI and DPI formulations of RPL554

Innovus Pharma preparing fo upcoming launch of FlutiCare nasal spray in US

Innovus Pharmaceuticals says that it has ordered 220,000 units of FlutiCare, an OTC fluticasone propionate nasal spray, in preparation for its US launch in the fourth quarter of 2017. The company says that it will launch a 120 spray version of the product for the treatment of allergic rhinitis. Innovus acquired the FlutiCare brand in 2015 when it acquired Novalere … [Read more...] about Innovus Pharma preparing fo upcoming launch of FlutiCare nasal spray in US

Endo files suit against Lupin for infringement of Nascobal nasal spray patents

Endo Pharmaceuticals filed suit against Lupin on July 28, 2017 alleging infringement of patents related to Par's Nascobal cyanocobalamin nasal spray. The suit was filed in the United States District Court for the Eastern District of Texas and was assigned to Judge Rodney Gilstrap. The patents cited in the suit include US patents 7,229,636; 7,404,489; 7,879,349; … [Read more...] about Endo files suit against Lupin for infringement of Nascobal nasal spray patents

Milestone Pharmaceuticals raises $55 million for development of intranasal etripamil

Milestone Pharmaceuticals has raised $55 million in a Series C financing round led by Novo Holdings A/S, the company said. The company plans to use the money to fund Phase 3 clinical development of etripamil, an intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). Earlier this year, Milestone announced positive … [Read more...] about Milestone Pharmaceuticals raises $55 million for development of intranasal etripamil

Opiant Pharmaceuticals reports results from Phase 1 study of intranasal naltrexone for alcohol use disorder

Opiant Pharmaceuticals has announced results from a Phase 1 trial of OPNT002 intranasal naltrexone, which it is developing for the treatment of alcohol use disorder (AUD). According to the company, which recently announced that it had licensed Aegis Therapeutics' Intravail absorption enhancers for use with its opioid antagonists, the addition of Intravail to … [Read more...] about Opiant Pharmaceuticals reports results from Phase 1 study of intranasal naltrexone for alcohol use disorder

Dewmar International files provisional patent application for inhaled cannabinoid lung cancer therapy

Dewmar International says that it has filed a provisional patent application titled "Cannabinoid Formulation to Treat Lung Cancer" with the United States Patent and Trademark Office (USPTO). The companies current brands include "Kush Cakes" psychedelic brownies and "Canna Energy" hemp drinks. According to Dewmar, "The invention relates to an inhalation … [Read more...] about Dewmar International files provisional patent application for inhaled cannabinoid lung cancer therapy